Development of Diagnostic System in Bone and Soft Tissue Sarcoma Targeting Tumor Derived Exosome

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K18466
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 56020:Orthopedics-related
• Research Institution: Okayama University (2019, 2021-2022); National Cancer Center Japan (2020)
• Principal Investigator: YOKOO Suguru 岡山大学, 医学部, 客員研究員 (00781204)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: リキッドバイオプシー / 液体生検 / 滑膜肉腫 / MCT1

Outline of Final Research Achievements

In this study, we identified monocarboxylate transporter 1 (MCT1), a protein present on the membrane surface of extracellular vesicles derived from synovial sarcoma (SS).
MCT1 was highly expressed in extracellular vesicles from SS patients, SS cell lines, and SS xenograft mouse. The expression of MCT1 in SS patients was decreased after treatment compared to before treatment. Furthermore, suppression of MCT1 in SS cell lines reduced tumor proliferation, migration, and invasion. MCT1 expression in cytoplasm and/or membrane of SS was associated with poor prognosis.
MCT1 labeling in SS can be a marker for early diagnosis and recurrence. It was also suggested that suppressing MCT1 has a potential in the treatment of SS.

Free Research Field

整形外科

Academic Significance and Societal Importance of the Research Achievements

予後不良の骨軟部肉腫の一つである滑膜肉腫におけるMCT1標識により早期診断や再発のマーカーとなり得る。またMCT1を抑制することで、滑膜肉腫の治療に役立つ可能性も示唆された。